Restricted Access: State Medicaid Coverage of Sofosbuvir Hepatitis C Treatment.

HEPATITIS C diagnosis; HEPATITIS C prevention; ANTIVIRAL agents; CHRONIC diseases; HEPATITIS C; INSURANCE; MEDICAID; NUCLEOTIDES; PATIENT Protection & Affordable Care Act; DISEASE complications; HEALTH services accessibility; LAW; ECONOMICS

Chronic hepatitis C (HCV) infection can persist for decades without symptoms. Many Americans are unaware of their infection status and are not receiving necessary care and treatment. This places them at greater risk for severe, even fatal, complications from the disease and increases the likelihood that they will transmit the virus to others. In late 2013, the Food and Drug Administration approved a direct acting antiviral drug called sofosbuvir to treat chronic HCV infection. Sofosbuvir is a highly effective, but very expensive, curative treatment for HCV. Unfortunately, the high price of sofosbuvir has led payers, including Medicaid, to restrict patient access. Looking at the sheer cost of the HCV crisis facing the United States, particularly among minority communities, it is a critical time to invest in prevention, screening, and treatment. These pharmaceutical treatments have the potential to cure HCV, eliminate the virus, and mitigate future health care expenses. This article argues that restricting access to this pharmaceutical treatment may be a discriminatory practice under both Medicaid law and the Affordable Care Act (ACA). In addition to potential legal challenges, there are strong economic and public health imperatives to removing barriers to HCV treatment. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Legal Medicine is the property of Routledge and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)